Evidence map›Paper›PMID 16821091›Full record

ArticleJournal of neuro-oncology2006

Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas.

Abderrahmane Hamlat, Stephan Saikali, Jacques Chaperon, Beatrice Carsin-Nicol, Michéle Le Calve, Thierry Lesimple, Mohamed Ben-hassel, Yvon Guegan

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Abderrahmane HamlatDepartment of Neurosurgery, CHU Pontchaillou, Rennes, France. hamlat.abd@wanadoo.fr
Stephan Saikali
Jacques Chaperon
Beatrice Carsin-Nicol
Michéle Le Calve
Thierry Lesimple
Mohamed Ben-hassel
Yvon Guegan
Hôpital Pontchaillou · FRCentre Eugène Marquis · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHistological, clinical and radiological features, and molecular genetic analysis are among the factors that have been considered in defining the prognosis of oligodendrogliomas (OD), but they have yielded conflicting results. The purpose of this study was to test out a scoring scale based on clinical, radiological, pathological and molecular features. MATERIAL AND

methodTo identify factors with prognostic significance, we analyzed 87 treated patients with a histological diagnosis of OD. Of the parameters analyzed, age, onset, clinical status, radiological enhancement, histological necrosis, mitosis and chromosomal anomalies emerged as significant prognosis factors using univariate analysis. Multivariate analysis revealed age and chromosomal anomalies as independent factors of survival.

resultsThe factors with a significant prognostic value were combined to determine which grouping factors best predict outcome. The proposed score is a pure number resulting from a combination of: 2 major factors: age and chromosomal anomalies (scored 3-0); 5 minor factors: onset, clinical examination, necrosis, mitoses (scored 1-0), and radiological enhancement (scored 2-0). According to our scale, 10 survival curves were produced for overall survival. Recursive partitioning of patients with the nearest score and outcome produced four groups with a significant difference in survival (p=10(-5)). The power of both the scale and the partitioned groups for predicting outcome was more accurate than the WHO and St Anne grading systems, and the molecular sub-classification.

conclusionsOur scale is a plausible way of classifying patients harboring intracranial OD according to expected survival.

Indexed as

AdolescentAdultAgedBrain NeoplasmsChildChild, PreschoolChromosomes, Human, Pair 1Diagnosis-Related GroupsFemaleGene DeletionGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMultivariate AnalysisNecrosis

Identifiers

PMID16821091
OpenAlexW2083984996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.